Lifordi Immunotherapeutics, Inc., a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) for autoimmune and inflammatory disorders, presented first-in-human data for LFD-200, a novel subcutaneously administered ADC delivering a potent glucocorticoid directly to immune cells. The data were shared at the EULAR 2026 European Congress of Rheumatology in London, UK, held June 3-6, 2026.
Phase 1 results from healthy participants demonstrated that LFD-200 was well tolerated and exhibited dose-responsive anti-inflammatory activity. Notably, the drug did not impact serum cortisol levels, a sensitive marker for systemic glucocorticoid toxicity. This finding is significant because systemic glucocorticoids, while effective for inflammation, are associated with serious side effects such as adrenal suppression, osteoporosis, and metabolic disturbances. By delivering the glucocorticoid directly to target cells, LFD-200 aims to minimize these systemic effects.
The study is currently enrolling patients with moderate to severe rheumatoid arthritis, with data expected by the end of 2026. Rheumatoid arthritis is a chronic autoimmune disease affecting millions worldwide, and current treatments often involve systemic immunosuppressants with significant toxicity. LFD-200 represents a potential advancement in targeted therapy, possibly offering a safer alternative for patients who require potent anti-inflammatory effects.
For those interested in more details, the full announcement including downloadable images and bios is available at www.lifordi.com.
Lifordi Immunotherapeutics is leveraging the success of ADCs to develop treatments for autoimmune and inflammatory conditions. The company’s lead ADC, LFD-200, has shown a favorable safety, pharmacokinetic, and pharmacodynamic profile in healthy volunteers, including dose-responsive anti-inflammatory activity without systemic glucocorticoid toxicity. Lifordi has also applied its drug delivery approach to other payloads such as antisense oligonucleotides, siRNA, and small molecules.
The implications of this announcement are substantial. If LFD-200 proves effective in patients, it could transform the treatment landscape for rheumatoid arthritis and potentially other autoimmune diseases by providing a targeted therapy that reduces systemic side effects. This could improve patient quality of life and adherence to treatment. Moreover, the technology platform may be applicable to other inflammatory conditions, broadening the impact of the approach.
Lifordi is backed by prominent investors including ARCH Venture Partners, Atlas Venture, 5AM Ventures, and Sanofi Ventures. The company is committed to changing how immune and inflammatory diseases are treated. Additional information can be found on their website and LinkedIn page.
